作为对抗阿尔茨海默氏症和糖尿病的潜在多目标治疗剂的Piperonal衍生的希夫基分子
Asif Ahmad1, Uzma Salar2, Musa Özil3
1Third World Center for Science and Technology, H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Future medicinal chemistry
|August 30, 2025
概括
新的Piperonal衍生希夫基显示对糖尿病和阿尔茨海默病酶的双重作用抑制. 这些化合物为两种疾病开发新疗法提供了有前途的策略.
科学领域:
- 医学化学
- 神经科学
- 药理学
背景情况:
- 糖尿病 (DM) 和阿尔茨海默氏症 (AD) 的同时出现需要开发多功能治疗剂.
- 皮皮隆衍生的希夫基因被探索为它们在DM和AD中涉及的向酶的潜力.
研究的目的:
- 合成和表征新型的来自皮佩罗纳的希夫基衍生物.
- 评估这些衍生物对DM (α-amylase和α-glucosidase) 和AD (乙胆酶和丁胆酶) 的关键酶的抑制潜力.
- 评估合成化合物的抗氧化特性.
主要方法:
- 来自Piperonal的希夫基衍生物的合成和结构特征.
- 在体外对α-氨基酶,α-葡萄糖酶,乙胆酶和丁胆酶进行酶抑制测定.
- 动力分析和分子对接研究.
- 对抗氧化剂活性进行评估.
主要成果:
- 化合物7和17分别对α- 葡萄糖酶和α- 氨基酶表现出强烈的抑制作用,其性能优于标准药物阿卡尔.
- 化合物7和9对乙胆酶和丁胆酶表现出显著的抑制作用,超过了多尼化的疗效.
- 合成的衍生品也显示出显著的抗氧化能力.
结论:
- 几种来自piperonal的希夫基衍生物显示出对糖尿病和阿尔茨海默病相关的目标具有有前途的双重作用的抑制作用.
- 这些化合物是开发新型治疗药物的潜在主要候选物,用于治疗并发性DM和AD.
- 进一步开发这些成功的候选人是有必要的.
更多相关视频
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.0K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
相关概念视频
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:15G Protein-coupled Receptors
13.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.3K